Insmed Q2 2024 revenue $90.3M (+17% YoY); net loss $300.6M; guides FY $340-360M

INSMED Inc

2024-Q2 EPS reported -$3.02 revenue$165,840,000

ARIKAYCE global revenue $90.3M in Q2 2024, up 17% YoY; U.S. $63.8M, Japan $21.1M, Europe $5.4M.
Net loss $300.6M ($1.94/sh) vs $244.8M loss ($1.78/sh) in Q2 2023; includes $103.7M non-cash fair value charge.
Reiterated FY2024 ARIKAYCE revenue guidance $340M-$360M, representing ~15% YoY growth at midpoint.
Completed public offering of 14.5M shares; net proceeds $713.2M. Redeemed $225M convertible notes due 2025.
Plan to file NDA for brensocatib in bronchiectasis in Q4 2024; Phase 3 ASPEN met primary endpoint with statistical significance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.